Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares moved down -6.17% in last trading session and ended the day at $8.06. HALO Gross Margin is 76.10% and its has a return on assets of -25.50%. Halozyme Therapeutics, Inc. (NASDAQ:HALO) quarterly performance is -48.27%.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) will webcast its Quarterly Update Conference Call for the fourth quarter and full year 2015 on Monday, February 29 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On the same date post-market, Halozyme will release financial results for the fourth quarter and year-ended December 31, 2015.
Penn West Petroleum Ltd. (NYSE:PWE) caters to the Basic Materials space. Its weekly performance is 30.99%. On the last day of trading company shares ended up at $0.97. Penn West Petroleum Ltd. (NYSE:PWE) distance from 50-day simple moving average (SMA50) is 23.29%.
On 16 February, Penn West Petroleum Ltd. (NYSE:PWE) has reached agreements to settle a bevy of class-action lawsuits stemming from accounting. The settlement in the Canadian and U.S. cases will be fully funded by the company’s insurance, meaning its cash resources and financial position won’t take a hit.
On 18 February, First Business Financial Services, Inc. (NASDAQ:FBIZ) shares fell -1.68% and was closed at $21.04. FBIZ EPS growth in last 5 year was 60.70%. First Business Financial Services, Inc. (NASDAQ:FBIZ) year to date (YTD) performance is -15.87%.
First Business Financial Services, Inc. (NASDAQ:FBIZ) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Saturday, Market Beat reports.
Denbury Resources Inc. (NYSE:DNR) shares fell -4.55% in last trading session and ended the day at $1.05. DNR Gross Margin is 99.60% and its has a return on assets of -29.10%. Denbury Resources Inc. (NYSE:DNR) quarterly performance is -72.00%.
Denbury Resources Inc. (NYSE:DNR) reported fourth-quarter and full-year 2015 results before markets opened Thursday. For the quarter, the oil and gas production company posted an adjusted diluted net loss per share of $0.01 on revenues of $344 million. In the same period a year ago, the company reported earnings per share (EPS) of $0.27 on revenues of $483.68 million.
Chimerix, Inc. (NASDAQ:CMRX) caters to the Healthcare space. Its weekly performance is 1.28%. On the last day of trading company shares ended up at $7.10. Chimerix, Inc. (NASDAQ:CMRX) distance from 50-day simple moving average (SMA50) is -25.38%.
Chimerix, Inc. (NASDAQ:CMRX) announced that detailed results from its Phase 3 SUPPRESS trial of brincidofovir in patients undergoing hematopoietic cell transplantation (HCT)will be presented Feb. 20 at the BMT Tandem Meetings in Honolulu.